Co-Investigator(Kenkyū-buntansha) |
竹中 克斗 愛媛大学, 医学系研究科, 教授 (30301295)
菊繁 吉謙 九州大学, 医学研究院, 講師 (40619706)
曽我 朋義 慶應義塾大学, 環境情報学部(藤沢), 教授 (60338217)
宮本 敏浩 九州大学, 医学研究院, 准教授 (70343324)
国崎 祐哉 九州大学, 大学病院, 准教授 (80737099)
|
Budget Amount *help |
¥154,050,000 (Direct Cost: ¥118,500,000、Indirect Cost: ¥35,550,000)
Fiscal Year 2020: ¥28,990,000 (Direct Cost: ¥22,300,000、Indirect Cost: ¥6,690,000)
Fiscal Year 2019: ¥30,160,000 (Direct Cost: ¥23,200,000、Indirect Cost: ¥6,960,000)
Fiscal Year 2018: ¥27,300,000 (Direct Cost: ¥21,000,000、Indirect Cost: ¥6,300,000)
Fiscal Year 2017: ¥26,520,000 (Direct Cost: ¥20,400,000、Indirect Cost: ¥6,120,000)
Fiscal Year 2016: ¥41,080,000 (Direct Cost: ¥31,600,000、Indirect Cost: ¥9,480,000)
|
Outline of Final Research Achievements |
We previously reported that TIM-3 is universally expressed malignant hematopoietic stem cells of human myeloid malignancies such as acute myelogenous leukemia (AML), myelodysplastic syndromes (MDS), and myeloproliferative neoplasms (MPN). TIM-3 is a functional molecule involved in the pathogenesis of human myeloid malignancies via utilizing TIM-3/galectin-9 autocrine loop. In this study, we focused on molecular mechanisms underlying the maintenance of stemness in human LSCs through the investigation of TIM-3-signaling and other LSCs-specific molecules that human myeloid LSCs universally depend upon. Through performing the multi-omics analysis, we successfully identified several novel LSCs-specific molecular or metabolic mechanisms including the downstream molecules involved in TIM-3-signaling. Furthermore, we also established the therapeutic models of human AML via targeting the novel LSCs-specific molecules in the project.
|